Acetyl Tetrapeptide-5 vs Argireline
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Acetyl Tetrapeptide-5 or Argireline?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Acetyl Tetrapeptide-5 and Argireline?
Argireline targets neuromuscular junction signaling (SNAP-25/SNARE complex) to reduce expression lines; Acetyl-tetrapeptide-5 targets vascular permeability and fluid retention around the eyes - different cosmetic targets entirely.
Evidence Comparison
Argireline (acetyl hexapeptide-3): manufacturer studies plus a small number of independent publications showing modest wrinkle reduction via SNAP-25 inhibition. Acetyl-tetrapeptide-5 (Eyeseryl): manufacturer data only, marketed for periorbital edema. Argireline has the edge with some independent validation.
Evidence Context Favoring Acetyl Tetrapeptide-5
Periorbital puffiness or under-eye edema research, accepting manufacturer-only evidence.
Evidence Context Favoring Argireline
Expression wrinkle reduction research where some independent data beyond manufacturer claims is desired.
Side-by-Side Snapshot
| Evidence grade | Acetyl Tetrapeptide-5: Level D Argireline: Level C |
|---|---|
| Research status | Acetyl Tetrapeptide-5: Preclinical Argireline: Preclinical |
| Primary category | Acetyl Tetrapeptide-5: Skin & Beauty Argireline: Skin & Beauty |
| Cited studies | Acetyl Tetrapeptide-5: 2 Argireline: 3 |